Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study

杜瓦卢马布 医学 奥西默替尼 不良事件通用术语标准 临床终点 回顾性队列研究 内科学 肿瘤科 危险系数 肺癌 比例危险模型 队列 不利影响 癌症 置信区间 腺癌 随机对照试验 无容量 免疫疗法 ROS1型
作者
Amin H. Nassar,So Yeon Kim,Jacqueline V. Aredo,Jamie Feng,Frances A. Shepherd,Chao Xu,David Kaldas,Jhanelle E. Gray,Thomas J. Dilling,Joel W. Neal,Heather A. Wakelee,Yufei Liu,Steven H. Lin,Tariq Abuali,Arya Amini,Yunan Nie,Tejas Patil,Anastasiya Lobachov,Jair Bar,Bailey Fitzgerald,Yu Fujiwara,Thomas U. Marron,Rohit Thummalapalli,Helena A. Yu,Dwight H. Owen,John Sharp,Saira Farid,Pedro Rocha,Edurne Arriola,Angelica D’Aiello,Haiying Cheng,Ryan M. Whitaker,Kaushal Parikh,Yash P. Ashara,Luxi Chen,K. Nathan Sankar,Jeremy P. Harris,Misako Nagasaka,Adanma Ayanambakkam,Ana I. Velazquez Mañana,Meera Vimala Ragavan,Jessica J. Lin,Zofia Piotrowska,M. Wilgucki,Joshua E. Reuss,H Lüders,Christian Grohé,Javier Espinar,Ellina Cheskis Feiner,Salman R Punekar,Shruti Gupta,Ticiana Leal,David J. Kwiatkowski,Raymond H. Mak,Elio Adib,Abdul Rafeh Naqash,Sarah B. Goldberg
出处
期刊:Journal of Thoracic Oncology [Elsevier]
标识
DOI:10.1016/j.jtho.2024.01.012
摘要

Introduction Durvalumab improves survival when used as consolidation therapy after chemoradiation (CRT) in patients with stage III NSCLC. However, the optimal consolidation therapy for patients with EGFR-mutant (EGFRmut) stage III NSCLC remains unknown. Methods In this multi-institutional international retrospective analysis across 24 institutions, we evaluated outcomes in patients with stage III EGFRmut NSCLC treated with concurrent CRT followed by consolidation therapy with osimertinib, durvalumab, or observation between 2015 and 2022. Kaplan-Meier method was used to estimate real-world progression-free survival (rwPFS, primary endpoint) and overall survival (OS, secondary endpoint). Treatment-related adverse events (trAE) during consolidation treatment were defined using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Multivariable Cox regression analysis was used. Results Of 136 patients with stage III EGFRmut NSCLC treated with definitive concurrent CRT, 56 received consolidation durvalumab, 33 received consolidation osimertinib, and 47 received observation alone. Baseline characteristics were similar across the 3 cohorts. With a median follow-up of 46 months for the entire cohort, the median duration of treatment was not reached (NR) for osimertinib (Inter-quartile range [IQR]: NR-NR) and was 5.5 (IQR:2.4-10.8) months with durvalumab. After adjusting for nodal status, stage III A/B/C, and age, patients treated with consolidation osimertinib had significantly longer 24-month rwPFS compared to those in the durvalumab or observation cohorts (osimertinib: 86%, durvalumab: 30%, observation: 27%, p<0.001 for both comparisons). There was no difference in rwPFS between durvalumab and the observation cohort. No significant difference in OS across the 3 cohorts was detected, possibly due to the limited follow-up. Any grade trAE occurred in 52% (2 [6.1%] grade ≥3) and 48% (10 [18%] grade ≥3) of patients treated with osimertinib and durvalumab, respectively. Of 45 patients who progressed on consolidation durvalumab, 37 (82%) subsequently received EGFR tyrosine kinase inhibitors (TKIs). Of these, 14 (38%) patients developed trAEs including 5 pneumonitis (14%; 2 [5.4%] grade ≥3) and 5 diarrhea (14%; 1 [2.7%] grade ≥3). Conclusions This study suggests that among patients with stage III unresectable NSCLC with a sensitizing EGFR mutation, consolidation osimertinib was associated with significantly longer rwPFS than durvalumab or observation. No unanticipated safety signals were observed with consolidation osimertinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
seven发布了新的文献求助10
3秒前
所所应助凉月采纳,获得10
4秒前
今后应助HCN采纳,获得10
4秒前
4秒前
5秒前
5秒前
mimi完成签到,获得积分10
5秒前
6秒前
敏敏完成签到,获得积分10
6秒前
朱广聚完成签到,获得积分10
6秒前
柯一一应助小可爱采纳,获得10
9秒前
0309发布了新的文献求助30
10秒前
无限绮波发布了新的文献求助10
10秒前
10秒前
852应助小鲤鱼吃大菠萝采纳,获得10
13秒前
斯文败类应助lion_wei采纳,获得10
14秒前
15秒前
无理完成签到 ,获得积分10
16秒前
香蕉觅云应助快乐每一天采纳,获得10
17秒前
HCN发布了新的文献求助10
17秒前
19秒前
陈文学发布了新的文献求助10
21秒前
小鲁完成签到,获得积分10
21秒前
23秒前
可爱的函函应助psj采纳,获得10
23秒前
27秒前
爆炸米花发布了新的文献求助10
27秒前
27秒前
27秒前
30秒前
酷波er应助yang采纳,获得10
31秒前
heiehi完成签到,获得积分10
31秒前
32秒前
狗儿吖完成签到,获得积分10
35秒前
36秒前
utf_8发布了新的文献求助10
36秒前
大模型应助shirley采纳,获得30
37秒前
37秒前
38秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 800
Chinese-English Translation Lexicon Version 3.0 500
Recherches Ethnographiques sue les Yao dans la Chine du Sud 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 460
Wisdom, Gods and Literature Studies in Assyriology in Honour of W. G. Lambert 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2394661
求助须知:如何正确求助?哪些是违规求助? 2098230
关于积分的说明 5287691
捐赠科研通 1825755
什么是DOI,文献DOI怎么找? 910296
版权声明 559972
科研通“疑难数据库(出版商)”最低求助积分说明 486511